Axicabtagene Ciloleucel in Patients With Relapsed/Refractory LBCL Ineligible for ASCT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial
Nat. Med. 2023 Sep 14;[EPub Ahead of Print], R Houot, E Bachy, G Cartron, FX Gros, F Morschhauser, L Oberic, T Gastinne, P Feugier, R Duléry, C Thieblemont, M Joris, F Jardin, S Choquet, O Casasnovas, G Brisou, M Cheminant, JO Bay, FL Gutierrez, C Menard, K Tarte, MH Delfau, C Portugues, E Itti, X Palard-Novello, P Blanc-Durand, Y Al Tabaa, C Bailly, C Laurent, F LemonnierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.